Gold prices tick higher on fresh U.S. tariff threats, Fed rate cut hopes
Director David P. Hochman of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) has recently purchased 20,000 shares of the company’s common stock at $2.75 per share, according to a Form 4 filing with the Securities and Exchange Commission. The total value of the purchase amounted to $55,000. The timing is notable as the stock has declined over 21% in the past week and 54% over six months, with InvestingPro data indicating oversold conditions.
The transaction, which occurred on August 4, 2025, involved the acquisition of shares by the DPH 2008 Trust, for which Hochman has indirect ownership. Following the transaction, the DPH 2008 Trust now holds 349,331 shares.
In addition to the shares held by the DPH 2008 Trust, Hochman directly owns 545,460 shares. He also has indirect ownership through the Solomon Ascher Hochman 2019 Trust, the Hannah Hochman 2019 Trust, the Judah Herman Hochman 2019 Trust, and the NSH 2008 Family Trust, holding 2,000, 2,000, 2,000, and 3,140 shares respectively.
Hochman is the Chief Executive Officer and Chairperson of Orchestra BioMed Holdings, Inc.
In other recent news, Orchestra BioMed Holdings, Inc. announced the initiation of an underwritten public offering of its common stock and pre-funded warrants. The company plans to provide underwriters with a 30-day option to purchase up to an additional 15% of the shares and pre-funded warrants sold in the offering. All securities are being offered by Orchestra BioMed itself. Meanwhile, Ocean Biomedical, Inc. disclosed that the Nasdaq Listing and Hearing Review Council has affirmed the decision to delist its securities from The Nasdaq Stock Market. This decision follows an earlier ruling by the Nasdaq Hearings Panel to delist the company’s shares and suspend trading. Ocean Biomedical had previously appealed the panel’s decision, but the appeal was denied. These developments have been shared through a press release and an SEC filing by the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.